Annexin Pharmaceuticals has taken an important step in its clinical development now that the first two patients have been treated in the ongoing Phase IIa study with the drug candidate ANXV in the eye diseases diabetic retinopathy and retinal vein occlusion.
Read the full article at biostock.se:
https://biostock.se/en/2025/12/annexin-avancerar-fas-iia-studie-genom-inledd-patientbehandling/
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/
Follow BioStock
Stay up to date with the latest news, upcoming events, recent videos, and podcasts! Subscribe to our newsletters at https://www.biostock.se/newsletter
Follow BioStock on social media: LinkedIn and Facebook!
About BioStock
BioStock is the leading digital hub for the Nordic life science sector. Focusing on biotechnology, medical technology, diagnostics, and drug development, we provide daily news updates, in-depth analyses, exclusive interviews, and innovation-promoting networking events – all to keep you informed about industry developments.
BioStock – Connecting Innovation & Capital.
© Modular Finance, source Nordic Press Releases